Gerald Illerhaus

10.7k total citations · 1 hit paper
86 papers, 2.4k citations indexed

About

Gerald Illerhaus is a scholar working on Neurology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Gerald Illerhaus has authored 86 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Neurology, 47 papers in Pathology and Forensic Medicine and 43 papers in Genetics. Recurrent topics in Gerald Illerhaus's work include CNS Lymphoma Diagnosis and Treatment (58 papers), Lymphoma Diagnosis and Treatment (47 papers) and Glioma Diagnosis and Treatment (38 papers). Gerald Illerhaus is often cited by papers focused on CNS Lymphoma Diagnosis and Treatment (58 papers), Lymphoma Diagnosis and Treatment (47 papers) and Glioma Diagnosis and Treatment (38 papers). Gerald Illerhaus collaborates with scholars based in Germany, Switzerland and United States. Gerald Illerhaus's co-authors include Jürgen Finke, Andrés J.M. Ferreri, Benjamin Kasenda, Elisabeth Schorb, Gabriele Ihorst, Kristina Fritsch, Emanuele Zucca, Carsten Hirt, R Mertelsmann and Gottfried Dölken and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Gerald Illerhaus

78 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Primary central nervous system lymphoma

2023 77 citations Andrés J.M. Ferreri, Teresa Calimeri et al. Nature Reviews Disease Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald Illerhaus Germany	29	1.6k	1.6k	1.3k	521	244	86	2.4k
Graham W. Slack Canada	24	1.7k 1.0×	571 0.4×	660 0.5×	1.1k 2.2×	278 1.1×	97	2.2k
Masataka Okamoto Japan	27	1.8k 1.1×	845 0.5×	738 0.6×	1.1k 2.1×	169 0.7×	77	2.5k
Ilske Oschlies Germany	26	1.7k 1.0×	554 0.3×	383 0.3×	916 1.8×	262 1.1×	87	2.1k
Emily K. Larsen United States	15	1.6k 1.0×	650 0.4×	421 0.3×	1.5k 2.9×	287 1.2×	28	2.6k
Alessandro Broccoli Italy	22	1.2k 0.8×	375 0.2×	326 0.3×	631 1.2×	262 1.1×	116	1.6k
Annalisa Chiappella Italy	23	1.3k 0.8×	506 0.3×	487 0.4×	782 1.5×	187 0.8×	111	1.7k
Gerardo Musuraca Italy	20	1.2k 0.7×	304 0.2×	532 0.4×	559 1.1×	292 1.2×	83	1.7k
Nicola Di Renzo Italy	24	944 0.6×	324 0.2×	631 0.5×	681 1.3×	277 1.1×	98	1.9k
Carla Casulo United States	19	1.3k 0.8×	257 0.2×	555 0.4×	1.1k 2.1×	147 0.6×	95	1.9k
Alice Di Rocco Italy	16	775 0.5×	317 0.2×	270 0.2×	466 0.9×	135 0.6×	64	1.1k

Countries citing papers authored by Gerald Illerhaus

Since Specialization

Citations

This map shows the geographic impact of Gerald Illerhaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Illerhaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Illerhaus more than expected).

Fields of papers citing papers by Gerald Illerhaus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Illerhaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Illerhaus. The network helps show where Gerald Illerhaus may publish in the future.

Co-authorship network of co-authors of Gerald Illerhaus

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Illerhaus. A scholar is included among the top collaborators of Gerald Illerhaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Illerhaus. Gerald Illerhaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wendler, Julia, Richard Lewis, Elke Valk, et al.. (2025). Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma. Haematologica. 110(6). 1384–1388.

Illerhaus, Gerald, Jeanette K. Doorduijn, Dorothee P. Auer, et al.. (2024). Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up. HemaSphere. 8(6). e89–e89. 5 indexed citations

Lorenzen, Sylvie, Claudia Pauligk, Eray Goekkurt, et al.. (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer. 23(1). 561–561. 5 indexed citations

Hammersen, Johanna, Sebastian Birndt, Konstanze Döhner, et al.. (2023). The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia. 37(9). 1879–1886. 11 indexed citations

Seifert, Nicole, Deepak Vangala, Sabine Seidel, et al.. (2023). Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients. HemaSphere. 7(8). e926–e926. 2 indexed citations

Ferreri, Andrés J.M., Teresa Calimeri, Kate Cwynarski, et al.. (2023). Primary central nervous system lymphoma. Nature Reviews Disease Primers. 9(1). 29–29. 77 indexed citations breakdown →

Groenland, Stefanie L., Alwin D. R. Huitema, Neeltje Steeghs, et al.. (2021). Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers. 13(24). 6281–6281. 14 indexed citations

Schorb, Elisabeth, Jürgen Finke, Gabriele Ihorst, et al.. (2019). Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer. 19(1). 287–287. 15 indexed citations

Schorb, Elisabeth, Benjamin Kasenda, Teresa Calimeri, et al.. (2017). Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice. Blood. 130. 376–376. 2 indexed citations

10.

Laquente, Berta, José A. López-Martín, Donald Richards, et al.. (2017). A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 17(1). 137–137. 53 indexed citations

11.

Ruf, C., et al.. (2014). Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma. BMC Surgery. 14(1). 5–5. 9 indexed citations

12.

Monsef, Ina, et al.. (2012). Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database of Systematic Reviews. 2012(11). CD009355–CD009355. 24 indexed citations

13.

Korfel, Agnieszka, Thomas Elter, E. Thiel, et al.. (2012). Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 98(3). 364–370. 76 indexed citations

14.

Fritsch, Kristina, Benjamin Kasenda, Claudia Hader, et al.. (2011). Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Annals of Oncology. 22(9). 2080–2085. 98 indexed citations

15.

Otto, Claudia, Abbas Agaimy, Alexander Braun, et al.. (2011). Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: A comparative clinical and histomorphological study of three cases including a new case of Carney triad. Diagnostic Pathology. 6(1). 52–52. 16 indexed citations

16.

Lagrèze, Wolf A., Jochen Rößler, Gerald Illerhaus, Wolfgang Maier, & Anca - Ligia Grosu. (2011). Therapie anterior gelegener Orbitatumoren. Der Ophthalmologe. 108(6). 519–530. 5 indexed citations

17.

Illerhaus, Gerald, Reinhard Marks, Fabian Müller, et al.. (2008). High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Annals of Oncology. 20(2). 319–325. 95 indexed citations

18.

Binder, Mascha, F.‐Nora Vögtle, Stefan Michelfelder, et al.. (2007). Identification of Their Epitope Reveals the Structural Basis for the Mechanism of Action of the Immunosuppressive Antibodies Basiliximab and Daclizumab. Cancer Research. 67(8). 3518–3523. 32 indexed citations

19.

Illerhaus, Gerald, Cornelius F. Waller, Annette I. Garbe, et al.. (2002). Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions. Annals of Hematology. 81(5). 273–281. 49 indexed citations

20.

Dölken, Gottfried, Gerald Illerhaus, Carsten Hirt, & R Mertelsmann. (1996). BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases.. Journal of Clinical Oncology. 14(4). 1333–1344. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact